Camidge and Gerber Emphasize the Importance of Face-to-Face Patient Connections
December 14th 2023Drs Camidge and Gerber highlight the ways that a liberal arts education can lay the foundation for a successful career in academic medicine; the importance and various forms of mentorship; and how clinical investigators can use their experiences and data to drive national policy changes.
Dr McArthur on Neoadjuvant Pembrolizumab Plus Chemotherapy in ER+/HER2– Breast Cancer
October 23rd 2023Heather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer.
Daily Adaptive Radiotherapy Delivers Improved Efficacy and Safety Outcomes in HNSCC
October 4th 2023Daily adaptive radiotherapy with 1-mm planning target volume margins is feasible in patients with head and neck squamous cell carcinoma and was associated with improved dosimetric parameters compared with standard radiotherapy.
Dr Desai on the Benefits and Limitations of Bladder Preservation With Chemoradiation in MIBC
September 28th 2023Neil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.
Dr Margulis on Key Considerations When Navigating Frontline Combination Regimens in RCC
September 26th 2023Vitaly Margulis, MD, discusses key disease characteristics and patient factors to consider when selecting between IO/IO vs IO/TKI treatment combinations for the management of patients with renal cell carcinoma.
Dr Wang on Switch Maintenance Therapy in Urothelial Carcinoma
Jue Wang, MD, professor, Department of Internal Medicine, member, Division of Hematology and Oncology, UT Southwestern Medical Center, discusses the benefits of switch maintenance therapy and individualized treatment strategies in patients with relapsed or refractory urothelial carcinoma.
Treatment Sequencing in Refractory Urothelial Carcinoma Requires a Personalized Approach
Jue Wang, MD, highlights key takeaways regarding treatment sequencing for patients with relapsed/refractory urothelial carcinoma and the key factors that could help inform decisions for individual patients.
VEGF and HIF Pathway Inhibition Point Toward an Increasingly Tolerable RCC Armamentarium
August 25th 2023Qian (Janie) Qin, MD, discusses the current RCC treatment landscape, ongoing research with belzutifan combination therapies, and considerations for investigating CAR T-cell therapy in patients with solid tumors.